On this page
PROCTOFOAM
pramoxine hydrochloride hydrocortisone acetate · Aerosol, Foam
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 086195-001 | PROCTOFOAM HC | AEROSOL, METERED | HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE | Prescription | BX | RLD RS |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Bioequivalence NOT established — insufficient data to determine equivalence
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 52 | Manufacturing (CMC) | Approved | January 21, 2021 | Unknown |
| Supplement | 38 | Labeling | Approved | December 6, 2004 | — |
| Supplement | 40 | Labeling | Approved | August 11, 2003 | — |
| Supplement | 37 | Labeling | Approved | August 11, 2003 | — |
| Supplement | 39 | Manufacturing (CMC) | Approved | January 3, 2003 | — |
| Supplement | 36 | Manufacturing (CMC) | Approved | April 21, 2000 | — |
| Supplement | 35 | Manufacturing (CMC) | Approved | November 29, 1999 | — |
| Supplement | 34 | Manufacturing (CMC) | Approved | January 12, 1999 | — |
| Supplement | 32 | Manufacturing (CMC) | Approved | August 7, 1998 | — |
| Supplement | 33 | Manufacturing (CMC) | Approved | May 7, 1998 | — |
| Supplement | 31 | Labeling | Approved | February 25, 1998 | — |
| Supplement | 30 | Manufacturing (CMC) | Approved | February 25, 1998 | — |
| Supplement | 29 | Manufacturing (CMC) | Approved | February 25, 1998 | — |
| Supplement | 28 | Manufacturing (CMC) | Approved | August 11, 1997 | — |
| Supplement | 27 | Manufacturing (CMC) | Approved | June 3, 1997 | — |
| Supplement | 25 | Manufacturing (CMC) | Approved | February 28, 1997 | — |
| Supplement | 24 | Labeling | Approved | January 26, 1995 | — |
| Supplement | 23 | Manufacturing (CMC) | Approved | November 16, 1994 | — |
| Supplement | 22 | Labeling | Approved | January 30, 1991 | — |
| Supplement | 21 | Labeling | Approved | August 28, 1990 | — |
| Supplement | 20 | Labeling | Approved | February 8, 1989 | — |
| Supplement | 15 | Manufacturing (CMC) | Approved | December 9, 1985 | — |
| Supplement | 10 | Manufacturing (CMC) | Approved | July 8, 1983 | — |
| Supplement | 11 | Manufacturing (CMC) | Approved | September 1, 1982 | — |
| Supplement | 8 | Manufacturing (CMC) | Approved | May 27, 1982 | — |
| Supplement | 9 | Manufacturing (CMC) | Approved | April 30, 1982 | — |
| Supplement | 6 | Manufacturing (CMC) | Approved | April 30, 1982 | — |
| Supplement | 5 | Manufacturing (CMC) | Approved | April 30, 1982 | — |
| Supplement | 4 | Manufacturing (CMC) | Approved | April 30, 1982 | — |
| Original application | 1 | Approved | July 26, 1978 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20250815). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Proctofoam ® HC is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the anal region.
Purpose
openFDA Drug LabelingPurpose Local anesthetic
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Apply to affected area 3 to 4 times daily. Use the applicator supplied for anal administration. For perianal use, transfer a small quantity to a tissue and rub in gently. Directions for Use. 1. Attach Cap: Place cap on top of container. 2. Shake Container: Shake foam container vigorously for 5-10 seconds before each use. Do not remove container cap during use of the product. 3. Attach Applicator: Hold container upright on a level surface and gently place the tip of the applicator onto the nose of the container cap. CONTAINER MUST BE HELD UPRIGHT TO OBTAIN PROPER FLOW OF MEDICATION. 4. Pull Plunger: Pull plunger past the fill line on the applicator barrel. 5. Prime Container: Hold the container and applicator at eye level. Place the index and middle fingers on the container cap flanges and the thumb beneath the container. Support the applicator with your other hand. Prime the container by pressing down firmly on flanges and then release. With initial priming, a burst of air may come out of the container. It usually requires 1-2 pumps for foam to appear. 6. Fill Applicator: To fill applicator barrel, press down firmly on cap flanges, hold for 1-2 seconds, and release. Wait 5-10 seconds to allow foam to expand in applicator barrel. Repeat until foam reaches fill line. It usually requires 3-4 pumps for foam to reach fill line. Remove applicator from container cap. Note: If foam goes beyond fill line, it will continue to expand and flow backwards resulting in foam build-up under cap. 7. Foam Application: Hold applicator firmly by barrel, making sure thumb and middle finger are positioned securely underneath and resting against barrel wings. Place index finger over the plunger. Gently insert tip into anus. Once in place, push plunger to expel foam, then withdraw applicator. CAUTION: Do not insert any part of the aerosol container directly into the anus. Apply to anus only with enclosed applicator. Do not insert any part of the applicator past the anus into rectum. 8. Clean Applicator: After each use, applicator parts should be pulled apart for thorough cleaning with warm water. Since some foam will appear under the cap, the cap and underlying tip should be pulled apart and rinsed to help prevent build-up of foam and possible blockage.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Topical corticosteroid products are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Warnings
openFDA Drug LabelingWarnings For external use only When using this product • do not exceed the recommended daily dosage unless directed by a doctor • do not put this product into the rectum by using fingers or any mechanical device or applicator • do not insert any part of the aerosol container into the rectum Stop use and ask a doctor if • rectal bleeding occurs • condition worsens or does not improve within 7 days • allergic reaction occurs to the ingredients in this product • symptom being treated does not subside • redness, irritation, swelling, pain or other symptoms develop or increase If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc. at 1-866-210-5948 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Description
openFDA Drug LabelingDESCRIPTION Proctofoam ® HC (hydrocortisone acetate 1% and pramoxine hydrochloride 1%) is a topical aerosol foam for anal use containing hydrocortisone acetate 1% and pramoxine hydrochloride 1% in a hydrophilic base containing cetyl alcohol, emulsifying wax, methylparaben, poly-oxyethylene-10-stearyl ether, propylene glycol, propylparaben, purified water, trolamine and inert propellants: isobutane and propane. Proctofoam ® HC contains a synthetic corticosteroid used as an anti-inflammatory/antipruritic agent and a local anesthetic. Hydrocortisone acetate Molecular weight: 404.50. Solubility of hydrocortisone acetate in water: 1 mg/100 mL. Chemical name: pregn-4-ene-3,20-dione, 21-(acetyloxy)-11,17-dihydroxy-,(11β)-. Pramoxine hydrochloride Molecular weight: 329.86. Pramoxine hydrochloride is freely soluble in water. Chemical name: morpholine, 4-[3-(4-butoxyphenoxy) propyl]-, hydrochloride. Hydrocortisone Acetate Structural Formula Pramoxine Hydrochloride Structural Formula
Active Ingredient
openFDA Drug LabelingActive ingredient Pramoxine hydrochloride 1%
Overdosage
openFDA Drug LabelingOVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (See PRECAUTIONS .)
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Proctofoam ® HC is supplied in an aerosol container with a special anal applicator. When used correctly, the aerosol container will deliver a minimum of 14 applications. NDC 0037-6822-10 10 g Store upright at controlled room temperature 20°-25°C (68°-77°F). DO NOT REFRIGERATE. Distributed by: Meda Pharmaceuticals Inc. Canonsburg, PA 15317 U.S.A. © 2025 Viatris Inc. PROCTOFOAM is a registered trademark of Alaven Pharmaceutical LLC, a Viatris Company. IN-682210-05 141371-0421
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: HYDROCORTISONE ACETATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Recalls
Source: FDA Enforcement| Classification | Reported | Firm | Reason | Status |
|---|---|---|---|---|
| Class II | February 2, 2022 | Mylan Pharmaceuticals Inc | cGMP deficiencies | Terminated |
| Class II | June 2, 2021 | Cardinal Health Inc. | CGMP Deviations: Intermittent exposure to temperature excursion during storage. | Terminated |
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 0037-6822-10 | 0037-6822 | Viatris Specialty LLC | 1 CANISTER in 1 CARTON (0037-6822-10) / 10 g in 1 CANISTER | August 15, 2014 |
| 0037-6823-15 | 0037-6823 | Viatris Specialty LLC | 1 CANISTER in 1 CARTON (0037-6823-15) / 15 g in 1 CANISTER | August 18, 2014 |
| 0037-6822 | 0037-6822 | Viatris Specialty LLC | — | August 15, 2014 |
| 0037-6823 | 0037-6823 | Viatris Specialty LLC | — | August 18, 2014 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
| Enforcement | FDA | Recall records |
Generated September 25, 2026 · 12 sections on this page.